Nicorette Mini Return Provides More Retail Therapy For Glaxo Consumer
This article was originally published in The Tan Sheet
Executive Summary
Following the February launch of its Flonase Allergy Relief OTC switch and the return of alli following a recall, Glaxo adds another momentum driver before the pending launch of its consumer product JV with Novartis by returning Nicorette minis as an OTC revenue source.
You may also be interested in...
Alli Return In U.S. Fattens Glaxo’s Consumer Outlook
GSK Consumer Healthcare says alli would be available starting Feb. 25 in most stores in the U.S. and Puerto Rico in “improved tamper-evident packaging.” Despite the product’s checkered history, its return marks another boost for Glaxo’s consumer outlook.
‘Clear’ Is In The Eye Of The Beholder, New York, CRN Argue In Age-Restricted Sales Litigation
CRN’s request for clarification, as it continues litigating complaint in US District Court for Southern New York, highlights what it contends is vague and overly general language in the legislation passed in October with a 22 April effective date.
Ultrahuman Expands Wearable Medtech Production Into US After $35M Funding Round
Firm operating in London, India and United Arab Emirates says its “Ultra Factory” will open in Indiana within the next six months with end-to-end production based on its operational facility in India.